Gilead’s Livdelzi wins FDA approval, can challenge Ocaliva dominance in primary biliary cholangitis…
The approval could present a major challenge to Ocaliva (obeticholic acid), which was until recently the sole approved drug for…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
primary biliary cholangitis
EMA grants Orphan Drug Designation to Saroglitazar Mg for treating patients with PBC
The Orphan drug status in Europe is given to medicines with the potential to be safe and effective treatments for rare,…
US FDA grants Orphan Drug Designation to Zydus’ Saroglitazar for primary biliary cholangitis…
This follows the grant of ‘Fast Track Designation’ by the USFDA to Saroglitazar Mg for PBC in December 2020
USFDA grants Zydus fast track designation for Saroglitazar to treat primary biliary cholangitis
Zydus announced that the United States Food and Drug Administration (USFDA) has granted ‘Fast Track Designation’ to Saroglitazar…
Zydus to present PBC and NASH clinical trial data of Saroglitazar Mg at AASLD event
The Liver Meeting Digital Experience 2020 is taking place virtually from November 13-16, 2020
Cadila Pharma launches Obetocad, generic obeticholic acid for liver therapy
Obetocad can be used as a monotherapy or along with UDCA for treatment of patients with primary biliary cholangitis who are…